General Catalyst Group Management, LLC
Position in PBLS — Parabilis Medicines, Inc.
CIK 1637946
Cambridge, MA
Position in PBLS
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$43,817,645
New position
Shares Held
1,600,937
first reported quarter
Ownership
1.30%
of shares outstanding
% of Portfolio
23.24%
of 13F equity value
Holder Rank
#14
of 79 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026General Catalyst Group Management, LLC holds $149,679,586 across 6 Biotechnology names. PBLS ranks #2 (29.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AVBP |
ArriVent BioPharma, Inc.
|
1,494,786 | $51,928,865 | |
| 2 | PBLS |
Parabilis Medicines, Inc.
This page
|
1,600,937 | $43,817,645 | |
| 3 | MAZE |
Maze Therapeutics, Inc.
|
1,035,910 | $30,911,554 | |
| 4 | ODTX |
Odyssey Therapeutics, Inc.
|
810,272 | $15,160,189 | |
| 5 | EIKN |
Eikon Therapeutics, Inc.
|
305,233 | $3,983,290 | |
| 6 | GUTS |
Fractyl Health, Inc.
|
4,884,186 | $3,878,043 |
All Filings in PBLS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $43,817,645 | 1,600,937 | Shares | Sole | 2026-08-17 | |
| No filing history on record for this holder in this stock. | ||||||